- Home
- UTMD vs ELDN Comparison
UTMD vs ELDN Comparison
Compare UTMD & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTMD
- ELDN
- Stock Information
- Founded
- UTMD 1978
- ELDN 2004
- Country
- UTMD United States
- ELDN United States
- Employees
- UTMD N/A
- ELDN N/A
- Industry
- UTMD Medical/Dental Instruments
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- UTMD Health Care
- ELDN Health Care
- Exchange
- UTMD Nasdaq
- ELDN Nasdaq
- Market Cap
- UTMD N/A
- ELDN 232.4M
- IPO Year
- UTMD N/A
- ELDN N/A
- Fundamental
- Price
- UTMD $55.84
- ELDN $3.23
- Analyst Decision
- UTMD
- ELDN Strong Buy
- Analyst Count
- UTMD 0
- ELDN 1
- Target Price
- UTMD N/A
- ELDN $16.00
- AVG Volume (30 Days)
- UTMD 17.2K
- ELDN 261.8K
- Earning Date
- UTMD 04-24-2025
- ELDN 03-20-2025
- Dividend Yield
- UTMD 2.17%
- ELDN N/A
- EPS Growth
- UTMD N/A
- ELDN N/A
- EPS
- UTMD 3.96
- ELDN N/A
- Revenue
- UTMD $40,903,000.00
- ELDN N/A
- Revenue This Year
- UTMD N/A
- ELDN N/A
- Revenue Next Year
- UTMD N/A
- ELDN N/A
- P/E Ratio
- UTMD $14.18
- ELDN N/A
- Revenue Growth
- UTMD N/A
- ELDN N/A
- 52 Week Low
- UTMD $55.81
- ELDN $1.52
- 52 Week High
- UTMD $77.33
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- UTMD 23.50
- ELDN 33.08
- Support Level
- UTMD $56.67
- ELDN $3.18
- Resistance Level
- UTMD $57.25
- ELDN $3.45
- Average True Range (ATR)
- UTMD 0.93
- ELDN 0.18
- MACD
- UTMD -0.06
- ELDN -0.00
- Stochastic Oscillator
- UTMD 0.00
- ELDN 22.77
Stock Price Comparison Chart: UTMD vs ELDN
■ UTMD
■ ELDN
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Share on Social Networks:
0